Related Experiment Video
Updated: Mar 18, 2026
Biofunctionalized Prussian Blue Nanoparticles for Multimodal Molecular Imaging Applications
Published on: April 28, 2015
Conjugating Prussian blue nanoparticles onto antigen-specific T cells as a combined nanoimmunotherapy
Rachel A Burga1,2,3, Shabnum Patel1,3, Catherine M Bollard1,4,5,3
1Institute for Biomedical Sciences, The George Washington University, Washington, DC, USA.
Aim:
To engineer a novel nanoimmunotherapy comprising Prussian blue nanoparticles (PBNPs) conjugated to antigen-specific cytotoxic T lymphocytes (CTL), which leverages PBNPs for their photothermal therapy (PTT) capabilities and Epstein-Barr virus (EBV) antigen-specific CTL for their ability to traffic to and destroy EBV antigen-expressing target cells.
Materials & Methods:
PBNPs and CTL were independently biofunctionalized. Subsequently, PBNPs were conjugated onto CTL using avidin-biotin interactions. The resultant cell-nanoparticle construct (CTL:PBNPs) were analyzed for their physical, phenotypic and functional properties.
Results:
Both PBNPs and CTL maintained their intrinsic physical, phenotypic and functional properties within the CTL:PBNPs.
Conclusion:
This study highlights the potential of our CTL:PBNPs nanoimmunotherapy as a novel therapeutic for treating virus-associated malignancies such as EBV+ cancers.
